Vol 8, No 6 (2019)
Research paper
Published online: 2020-01-23

open access

Page views 1065
Article views/downloads 602
Get Citation

Connect on Social Media

Connect on Social Media

Role of serum allograft inflammatory factor-1 (AIF-1) in Egyptian type 2 diabetic patients

Mona Kamal ElDeeb1, Gihane Ibrahim Khalil1, Moatez Ahmed Zaki1, El-Sayed Mehana1, Sahar Omer1
Clin Diabetol 2019;8(6):271-276.

Abstract

Background. Diabetes mellitus (DM) is a powerful and independent risk factor for cardiovascular disease. The atherosclerosis process in diabetes is indistinguishable from that of the nondiabetic population, but it begins earlier and is often more extensive and more severe. AIF-1 promotes chemotaxis, spreading and migration of macrophages and vascular smooth muscle cells (VSMCs) which suggest a role of AIF-1 in the atherosclerotic plaque formation. Thus, this study determines the role of AIF-1 in the Egyptian type 2 diabetic patients.

Results. The level of AIF-1 was significantly higher in the type 2 diabetic group when compared to the control group (p = 0.000). In type 2 diabetic patients group, there was a significant positive correlation between CIMT and AIF-1 (r = 0.468, p = 0.000). In addition to the positive correlation between CIMT and AIF-1, CIMT in regression model analysis was significantly positive contributing to the outcome variable (AIF-1) (p < 0.05), denoting the possible role of elevated serum AIF-1 level in atherosclerotic process with further studies on larger scale needed.

Article available in PDF format

View PDF Download PDF file

References

  1. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008; 371(9626): 1800–1809.
  2. Inzucchi SE, Sherwin RS. Diabetes mellitus. In: Cecil Medicine. Goldman L, Ausiello D (eds). 23rd Ed. Elsevier Saunders Company, Phildelphia. 2008: 1727–1759.
  3. Tian Y, Jain S, Kelemen SE, et al. AIF-1 expression regulates endothelial cell activation, signal transduction, and vasculogenesis. Am J Physiol Cell Physiol. 2009; 296(2): C256–C266.
  4. Tian Y, Kelemen SE, Autieri MV. Inhibition of AIF-1 expression by constitutive siRNA expression reduces macrophage migration, proliferation, and signal transduction initiated by atherogenic stimuli. Am J Physiol Cell Physiol. 2006; 290(4): C1083–C1091.
  5. Ninomiya H, Katakami N, Sato I, et al. Association between subclinical atherosclerosis markers and the level of accumulated advanced glycation end-products in the skin of patients with diabetes. J Atheroscler Thromb. 2018; 25(12): 1274–1284.
  6. Rocha VZ, Santos RD. Subclinical carotid vascular disease and risk factors for atherosclerosis in type 1 and type 2 diabetes. Arch Endocrinol Metab. 2017; 61(2): 105–107.
  7. Lau KK, Wong YK, Chan YH, et al. Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with type 2 diabetes. Cardiovasc Diabetol. 2012; 11: 101.
  8. Nandalur KR, Baskurt E, Hagspiel KD, et al. Calcified carotid atherosclerotic plaque is associated less with ischemic symptoms than is noncalcified plaque on MDCT. AJR Am J Roentgenol. 2005; 184(1): 295–298.
  9. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459–2472.
  10. Linton MRF, Yancey PG, Davies SS, et al. et al.. The role of lipids and lipoproteins in atherosclerosis. 2019 Jan 3. In: Endotext Feingold KR, Anawalt B, Boyce A, et al. (eds). South Dartmouth (MA): MDText.com, Inc.; 2000.
  11. Ravnskov U, Ravnskov U, Ravnskov U. Is atherosclerosis caused by high cholesterol? QJM. 2002; 95(6): 397–403.
  12. Liu G, Ma H, Jiang L, et al. Allograft inflammatory factor-1 and its immune regulation. Autoimmunity. 2007; 40(2): 95–102.
  13. McDaniel D, Zhou X, Rigney D, et al. Allograft inflammatory factor-1 in cardiac ischemia re-perfusion injury: release of molecular markers in an in vitro setting. Open Journal of Organ Transplant Surgery. 2013; 03(01): 5–12.
  14. Zhao YY, Yan DJ, Chen ZW. Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes. Cell Immunol. 2013; 284(1-2): 75–83.
  15. Lewit-Bentley A, Réty S. EF-hand calcium-binding proteins. Curr Opin Struct Biol. 2000; 10(6): 637–643.
  16. Autieri MV, Carbone C, Mu A. Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury. Arterioscler Thromb Vasc Biol. 2000; 20(7): 1737–1744.
  17. Autieri MV. cDNA cloning of human allograft inflammatory factor-1: tissue distribution, cytokine induction, and mRNA expression in injured rat carotid arteries. Biochem Biophys Res Commun. 1996; 228(1): 29–37.
  18. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol. 2007; 7(6): 467–477.
  19. Autieri MV, Kelemen SE, Wendt KW. AIF-1 is an actin-polymerizing and Rac1-activating protein that promotes vascular smooth muscle cell migration. Circ Res. 2003; 92(10): 1107–1114.
  20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31–41.
  21. Sacks DB. Diabetes Mellitus. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE (eds). 5th Ed. Elsevier Saunders Company‚ St Louis. 2012: 1441–1447.
  22. Hortin GL. Amino acids, peptides, and proteins. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE (eds). 5th Ed. Elsevier Saunders Company‚ St Louis. 2012: 538–539.
  23. Fukui M, Tanaka M, Asano M, et al. Serum allograft inflammatory factor-1 is a novel marker for diabetic nephropathy. Diabetes Res Clin Pract. 2012; 97(1): 146–150.
  24. Kirkpatrick LA, Feeney BCA. Gimple guide to IBM SPSS Statistics for Version 20. Wadsworth, Cengage Learning, Belmont, Calif. 2013.
  25. Vijayaraghavan K. Treatment of dyslipidemia in patients with type 2 diabetes. Lipids Health Dis. 2010; 9: 144.
  26. Zaki NF, Sulaiman AS, Gillani WS. Clinical evaluation of Dyslipidemia among type II diabetic patients at Public hospital Penang, Malaysia. Int Arch Med. 2010; 3: 34.
  27. Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology. 2012; 217(5): 483–491.
  28. Lorente-Cebrián S, Decaunes P, Dungner E, et al. Allograft inflammatory factor 1 (AIF-1) is a new human adipokine involved in adipose inflammation in obese women. BMC Endocr Disord. 2013; 13: 54.
  29. Berglund LM, Kotova O, Osmark P, et al. NFAT regulates the expression of AIF-1 and IRT-1: yin and yang splice variants of neointima formation and atherosclerosis. Cardiovasc Res. 2012; 93(3): 414–423.
  30. Kelemen SE, Autieri MV. Expression of allograft inflammatory factor-1 in T lymphocytes: a role in T-lymphocyte activation and proliferative arteriopathies. Am J Pathol. 2005; 167(2): 619–626.